James P. Stice

BridgeBio (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index1.4kcitations73works3.32yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

FOXO transcription factor regulation(15), Cancer, Hypoxia, and Metabolism(13), Nitric Oxide and Endothelin Effects(11), Advanced Breast Cancer Therapies(10), Estrogen and related hormone effects(9)

Publications73 total

Abstract A063: BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models

Molecular Cancer Therapeutics·2025

Abstract C082: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia

Molecular Cancer Therapeutics·2025

Abstract PS7-04: BBO-10203, a first-in-class, orally bioavailable, selective blocker of the PI3Kα:RAS interaction inhibits tumor growth alone and in combination with standard of care therapies in breast cancer models without inducing hyperglycemia

1 cited

Clinical Cancer Research·2025· 1 cited

BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction

13 cited

Science·2025· 13 cited

Abstract 3788: BBO-8520, a first-in-class direct dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C, exhibits robust efficacy in non-small cell lung cancer preclinical models

Cancer Research·2025

Supplementary Figure S6 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Table S2 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Figure S2 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Figure S3 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Table S1 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Figure S4 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Figure S5 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Figure S1 from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Supplementary Material and Methods from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Data from Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

2025Open Access

Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C

33 cited

Cancer Discovery·2024· 33 citedOpen Access

9 Oral: BBO-10203, an orally bioavailable small molecule that disrupts the RAS-PI3Kα interaction leading to pAKT and tumor growth inhibition in models of breast, lung and colorectal cancer

European Journal of Cancer·2024

Abstract RF02-02: BBO-10203, a first-in-class, orally bioavailable, selective covalent small molecule that inhibits RAS-driven PI3Kalpha activity without affecting glucose metabolism

6 cited

Cancer Research·2024· 6 cited

Abstract ND07: BBO-8520, a first-in-class, direct inhibitor of KRASG12C (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding

10 cited

Cancer Research·2024· 10 cited

Abstract A084: Use of the natural nucleotide, GTP, is essential for the identification of potent, active-state KRASG12C inhibitors that bind in the switch II pocket

Molecular Cancer Therapeutics·2023

page 1 of 4Next →

Frequent Co-authors

Donald P. McDonnell(21), Suzanne E. Wardell(20), Rachid Safi(14), Kerstin W. Sinkevicius(13), Pedro J. Beltran(13), Felice C. Lightstone(12), Dwight V. Nissley(12), Anne A. Knowlton(11), Holly M. Alley(11), Keshi Wang(11), Dhirendra K. Simanshu(11), Frank McCormick(11), Rui Xu(10), Andrew G. Stephen(10), Eli Wallace(10), John D. Norris(9), Scott A. Lawrence(9), Marcin Dyba(9), Yue Yang(9), Bryan D. Smith(9)